Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA.
DNA aptamer
SELEX
biomarker
cancer
cancer therapy
microscale thermophoresis (MST)
surface plasmon resonance spectroscopy (SPR)
uPA
uPAR
urokinase
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Apr 2022
28 Apr 2022
Historique:
received:
12
04
2022
revised:
25
04
2022
accepted:
26
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Urokinase-type plasminogen activator is widely discussed as a marker for cancer prognosis and diagnosis and as a target for cancer therapies. Together with its receptor, uPA plays an important role in tumorigenesis, tumor progression and metastasis. In the present study, systematic evolution of ligands by exponential enrichment (SELEX) was used to select single-stranded DNA aptamers targeting different forms of human uPA. Selected aptamers allowed the distinction between HMW-uPA and LMW-uPA, and therefore, presumably, have different binding regions. Here, uPAapt-02-FR showed highly affine binding with a K
Identifiants
pubmed: 35563278
pii: ijms23094890
doi: 10.3390/ijms23094890
pmc: PMC9100121
pii:
doi:
Substances chimiques
Aptamers, Nucleotide
0
Ligands
0
Urokinase-Type Plasminogen Activator
EC 3.4.21.73
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Federal Ministry of Education and Research
ID : 16SV6072
Organisme : Federal Ministry of Education and Research
ID : 16SV6070
Organisme : Ministerium für Wissenschaft, Forschung und Kultur
ID : 85017631
Références
Int J Mol Sci. 2021 Apr 09;22(8):
pubmed: 33918821
Biotechniques. 2007 Sep;43(3):344, 346, 348 passim
pubmed: 17907577
Expert Opin Biol Ther. 2001 Jul;1(4):683-91
pubmed: 11727504
Cancer Res. 1991 Jan 1;51(1):274-81
pubmed: 1988089
Curr Med Chem. 2011;18(27):4139-51
pubmed: 21838691
Blood. 1997 Oct 1;90(7):2738-46
pubmed: 9326241
RNA. 2010 Dec;16(12):2360-9
pubmed: 20962041
Curr Med Chem. 2011;18(27):4126-38
pubmed: 21838692
Expert Opin Ther Targets. 2016;20(5):551-66
pubmed: 26667094
Thromb Haemost. 2005 Apr;93(4):779-86
pubmed: 15841327
Cancer Treat Rev. 2008 Apr;34(2):122-36
pubmed: 18162327
Front Biosci (Landmark Ed). 2009 Jan 01;14(4):1337-61
pubmed: 19273134
J Biol Chem. 1995 Jul 21;270(29):17375-80
pubmed: 7615542
Talanta. 2022 Feb 1;238(Pt 1):122971
pubmed: 34857318
Mol Cancer Res. 2012 Dec;10(12):1532-43
pubmed: 23038812
Analyst. 2019 Oct 21;144(20):6064-6073
pubmed: 31528891
Med Res Rev. 2014 Sep;34(5):918-56
pubmed: 24549574
Cancers (Basel). 2022 Jan 19;14(3):
pubmed: 35158766
Methods Mol Biol. 2016;1380:99-111
pubmed: 26552819
FEBS Lett. 2002 Sep 25;528(1-3):212-6
pubmed: 12297307
Expert Rev Mol Diagn. 2011 Jul;11(6):617-34
pubmed: 21745015
Nucleosides Nucleotides Nucleic Acids. 2004 Oct;23(6-7):891-3
pubmed: 15560078
DNA Cell Biol. 2001 May;20(5):297-305
pubmed: 11410166
PLoS One. 2015 Mar 20;10(3):e0119207
pubmed: 25793507
Int J Mol Sci. 2021 Apr 16;22(8):
pubmed: 33923400
Curr Protoc Mol Biol. 2006 Aug;Chapter 10:Unit 10.2A
pubmed: 18265373
J Biol Chem. 1988 Aug 15;263(23):11189-95
pubmed: 2969891
Nat Rev Drug Discov. 2017 Mar;16(3):181-202
pubmed: 27807347
Front Oncol. 2018 Feb 12;8:24
pubmed: 29484286
J Biochem. 1981 Jul;90(1):225-32
pubmed: 7026550
Biotechniques. 2007 May;42(5):578, 580, 582
pubmed: 17515195
Nucleic Acids Res. 1981 Jul 10;9(13):3047-60
pubmed: 6269071